Kyv-101

5 trials 3 recruiting NNeurology/Psychiatry Orphan designation

Filter these 5 trials by condition, phase, country and more.

Open in Search →

5 Registered trials

3 Recruiting

0 Completed trials

2 Sponsors

4 Countries

Phase II/III

Phase II

Phase I/II

Phase II/III: 2 Phase II: 1 Phase I/II: 2

Oversight events:

1 serious breach across 1 trial

View oversight register →

Indications tested

Rheumatoid arthritis 2 Myasthenia gravis 2 Lupus nephritis 1 Progressive multiple sclerosis 1 Nervous system disorder 1 Stiff person syndrome 1

Sponsors using this IMP

Kyverna Therapeutics Inc. 3 Charite Universitaetsmedizin Berlin KöR 2

All trials

5 total

A Study of Anti-CD19 CAR T-cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis Pending

2024-511168-10-00 Phase II 4 countries Kyverna Therapeutics Inc.
Anti-CD 19 CAR-T cell therapy in patients with ANCA Vasculitis - the IDEAL trial Pending

2024-517303-36-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
Not Applicable Recruiting

2024-511198-31-00 Phase II/III 1 country Kyverna Therapeutics Inc.
COMparison of B-cell dePletion by rituximAb and anti-CD 19 CAR-T therapy in patients with rhEumatoid arthritis- The COMPARE TRIAL Recruiting

2024-514955-13-00 Phase I/II 1 country Charite Universitaetsmedizin Berlin KöR
A Study of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy, in Subjects With Generalized Myasthenia Gravis Recruiting

2023-509892-17-00 Phase II/III 1 country Kyverna Therapeutics Inc.

Showing 1–5 of 5 trials

← All drugs A–Z